Curex Medical Leadership and Credentials: What You Need to Know

Who Runs Curex? Medical Leadership Transparency

Telehealth platforms that prescribe controlled-adjacent medications, including GLP-1 receptor agonists, are required by state medical boards to have a licensed physician or physician group ultimately responsible for clinical decisions. Curex does not prominently name its Chief Medical Officer or Medical Director on its public-facing website, which makes independent verification difficult for prospective patients.

What Public Records Reveal

A search of state medical board databases, the National Provider Identifier (NPI) registry at the Centers for Medicare and Medicaid Services, and the Federation of State Medical Boards (FSMB) physician finder does not surface a single clearly affiliated Curex medical director as of this writing. That absence does not confirm wrongdoing, but it does mean patients cannot easily cross-check disciplinary history, board certifications, or specialty training before enrolling.

Legitimate telehealth companies typically publish:

• The full legal name and NPI of the supervising or medical director physician
• Board certification details (for example, American Board of Obesity Medicine or American Board of Internal Medicine)
• The state(s) in which the medical director holds an active, unrestricted license

Curex provides none of these in an easily accessible format. Patients should request this information directly before any consultation.

Why This Matters for GLP-1 Prescribing

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy states: "Obesity pharmacotherapy should be prescribed by clinicians with training in obesity medicine and within the context of a comprehensive treatment program." [1] Prescribing semaglutide or tirzepatide without a qualified obesity-trained clinician overseeing the program does not meet that standard. Patients have every right to ask for the prescribing physician's name, license number, and board certification before accepting a prescription.

Is Curex Legit? Regulatory and Licensing Standing

The word "legit" covers several separate questions: Is the business legally incorporated? Are its physicians licensed in your state? Are the medications it dispenses FDA-approved or legally compounded? Each question has a different answer.

Business Registration and BBB Standing

Curex is an incorporated entity operating under U.S. Law. The Better Business Bureau (BBB) maintains a profile for Curex; prospective patients should check BBB.org directly for the current rating and complaint volume, because both figures change over time. As of public records reviewed for this article, Curex has accumulated consumer complaints related to billing, subscription cancellations, and medication delays. The BBB complaint pattern does not by itself indicate clinical negligence, but billing and fulfillment problems at telehealth companies sometimes reflect understaffing at the clinical level as well.

LegitScript Certification

LegitScript is the verification body that Google, Meta, and most major ad platforms require online pharmacies and telehealth prescribers to pass before running paid advertising. A LegitScript "certified" badge indicates the platform has verified its pharmacy partnerships, physician licensing, and prescribing practices. Curex does not display a LegitScript certification badge as of this review. Patients should verify current status at legitscript.com before providing payment information.

State-by-State Telehealth Licensing

Prescribing a medication across state lines requires the prescribing physician to hold an active license in the patient's state of residence, per the Federation of State Medical Boards interstate telehealth guidelines and individual state medical practice acts. [2] Curex does not publish a complete list of states where it operates. Before signing up, patients in any state should ask: "Is there a physician licensed in my state affiliated with this platform who will be responsible for my prescription?"

The GLP-1 Medications Curex Offers

Curex markets both branded and compounded versions of GLP-1 receptor agonists. The distinction between the two has significant safety and legal implications.

FDA-Approved Branded GLP-1s

The FDA has approved two injectable GLP-1 receptor agonists specifically for chronic weight management in adults:

• Semaglutide 2.4 mg (Wegovy): Approved June 2021. In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001). [3]
• Tirzepatide 2.5 to 15 mg (Zepbound): Approved November 2023. In the SURMOUNT-1 trial (N=2,539), the 15 mg tirzepatide dose produced a mean weight reduction of 20.9% at 72 weeks versus 3.1% with placebo (P<0.001). [4]

Both drugs carry FDA-required prescribing information including a black-box warning for thyroid C-cell tumors observed in rodent studies, and both require ongoing clinical monitoring per the prescribing information. [5][6]

Compounded Semaglutide: A Critical Legal Issue

During a period when branded semaglutide was on the FDA drug shortage list, 503B outsourcing facilities were legally permitted to compound semaglutide under specific conditions. The FDA removed semaglutide injections from the shortage list in early 2025, which means that compounding of semaglutide by most 503A pharmacies became impermissible after that date. [7]

Curex, like many GLP-1 telehealth platforms, marketed compounded semaglutide during the shortage window. Whether it has fully transitioned patients to FDA-approved branded products following the shortage resolution is not clearly communicated on its website. Patients receiving compounded semaglutide after the shortage ended are receiving a medication that the FDA considers illegally compounded, and they deserve a direct answer from Curex about what they are actually being dispensed.

Dosing and Titration Protocols

The standard Ozempic/Wegovy titration schedule begins at 0.25 mg weekly for four weeks, with dose escalation every four weeks up to the maintenance dose of 2.4 mg for Wegovy. [5] Any telehealth platform that accelerates this titration schedule without documented clinical justification, or that fails to screen for contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, is not following FDA-labeled dosing guidance.

Clinical Oversight and Follow-Up Protocols

A prescription alone is not adequate care for GLP-1 therapy. The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends baseline and periodic monitoring of:

• Weight, blood pressure, and heart rate at each visit
• HbA1c and fasting glucose in patients with prediabetes or diabetes
• Lipid panel annually
• Renal function in patients with kidney disease history [8]

What Curex's Protocol Appears to Include

Curex's publicly described workflow centers on an online questionnaire, a short telehealth visit (synchronous or asynchronous, depending on state), and prescription fulfillment. Whether it systematically orders baseline labs or schedules follow-up visits at the AACE-recommended intervals is not clearly described in its patient-facing materials.

Platforms that rely exclusively on self-reported questionnaires without objective lab data before initiating a GLP-1 prescription are operating at the lower end of the clinical oversight spectrum. That is not unique to Curex among cash-pay GLP-1 telehealth companies, but it is a legitimate concern.

Contraindication Screening

Absolute contraindications to semaglutide and tirzepatide include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and known hypersensitivity to the active ingredient. [5][6] Patients with a history of pancreatitis, gallbladder disease, or severe gastrointestinal disorders require careful risk-benefit discussion before initiation. A questionnaire-only intake process may not reliably surface all relevant history.

Curex Complaints: What Patients Are Reporting

Across public review platforms including BBB, Trustpilot, and Reddit, a consistent set of complaints about Curex has emerged. HealthRX categorizes these into three operational domains:

Billing and Subscription Disputes

The most common complaint category involves difficulty canceling subscriptions and unexpected charges after patients attempt to stop service. Multiple BBB complaints describe charges continuing after cancellation requests were submitted. This pattern is not clinically dangerous in itself, but it reflects organizational practices that affect patient trust.

Medication Fulfillment Delays

A second category involves delays between prescription issuance and medication arrival. GLP-1 medication delays matter clinically because patients titrating doses may run out before their next shipment, creating unplanned treatment interruptions. Abrupt discontinuation of semaglutide or tirzepatide can lead to rapid weight regain, as shown in the STEP-4 withdrawal trial, where participants who stopped semaglutide regained two-thirds of their lost weight within one year. [9]

Inadequate Clinical Follow-Up

A smaller but clinically significant complaint category involves patients reporting difficulty reaching a medical provider when they experienced side effects, including nausea, vomiting, and injection-site reactions. GLP-1 class side effects affect the majority of users: in STEP-1, gastrointestinal adverse events occurred in 74.2% of the semaglutide group. [3] Access to a clinician during dose escalation is not optional. It is the standard expected by the Endocrine Society and AACE guidelines.

How to Verify Any GLP-1 Telehealth Platform Before Enrolling

Given the gaps in Curex's public-facing disclosure, the same verification checklist applies to any cash-pay GLP-1 telehealth service.

Five-Step Verification Checklist

1. Ask for the prescribing physician's full name and NPI. Look up that NPI at nppes.cms.hhs.gov to confirm the physician is real, licensed, and active.
2. Check the physician's license in your state at your state medical board website (findable via the FSMB directory at fsmb.org).
3. Check for disciplinary actions through the FSMB DocInfo tool at docinfo.org.
4. Confirm pharmacy accreditation. Ask which pharmacy will fulfill your prescription and check that pharmacy's NABP accreditation at nabp.pharmacy.
5. Verify LegitScript status at legitscript.com/lookup before paying.

No legitimate prescriber or platform should hesitate to answer any of these questions. Refusal or evasion is itself a red flag.

What Good Looks Like: Benchmarks for GLP-1 Telehealth Credentialing

Not all telehealth GLP-1 platforms operate identically. Patients deserve a clear benchmark.

Medical Leadership Standards

The Obesity Medicine Association (OMA) offers board certification in obesity medicine (Diplomate, OMA or American Board of Obesity Medicine). A platform whose medical director holds ABOM certification has at minimum demonstrated formal competency in obesity pharmacotherapy.

Prescribing Volume and Supervision Ratios

State medical boards in some states cap the number of patients a telemedicine-only physician may supervise. California, for instance, has specific supervisory ratio rules for collaborative practice agreements. Patients in regulated states should ask whether the platform complies with those ratios.

Transparent Pricing and No Surprise Billing

The No Surprises Act (effective January 2022) requires most health care providers to give patients good-faith cost estimates before service. [10] Cash-pay telehealth platforms operating outside insurance may not always fall under its full scope, but ethical platforms provide itemized pricing for the consultation, medication, and any follow-up visits before collecting payment.

The Bottom Line on Curex's Medical Credentials

Curex has operated in the telehealth space, originally in allergy immunotherapy and more recently in GLP-1 weight management. The core problem for prospective patients is opacity: the platform does not publicly name or document its medical leadership in a way that allows independent verification through state board databases or the NPI registry.

That opacity does not automatically make Curex illegal or dangerous. Physicians employed by telehealth platforms are not always listed on marketing pages. But patients making decisions about medications with a black-box thyroid warning and a requirement for ongoing monitoring deserve to know who is responsible for their care. Ask before you pay.

The FDA's guidance on choosing a safe online pharmacy, published at fda.gov, advises patients to use only sites that require a valid prescription from a licensed prescriber and that are licensed by the state board of pharmacy. [11] Those two criteria remain the minimum floor. Curex patients should verify both before beginning treatment.